Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML

This study aims to evaluate the efficacy and safety of venetoclax combined with homoharringtonine and cytarabine in the treatment of newly diagnosed acute myeloid leukemia.

Trial Details

NCT ID
NCT05805098
Phase
PHASE2 / PHASE3
Sponsor
The First Affiliated Hospital of Soochow University
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Venetoclax
  • Homoharringtonine
  • Cytarabine
Locations (sample)
  • Suzhou, Jiangsu, China|31.30408,120.59538

Key Eligibility Criteria

  • Patients who sign the informed consent must have the ability to understand and be willing to participate in the study and sign the informed consent.
  • patients must have confirmation of AML by WHO criteria, previously untreated, and eligible for treatment with intensive chemotherapy as defined by …
  • Patients \> 18 to ≤ 60 years
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →